% | $
Quotes you view appear here for quick access.

Optimer Pharmaceuticals, AŞ Message Board

  • alternatepatel alternatepatel Jun 27, 2013 3:13 PM Flag

    Amylin AMLN: Michael King from Roadman & R said it was worth less than 10$, AZN+BMS acquired it for 31$

    Amylin AMLN: Michael King from Roadman & Renshaw said it was worth less than 10$ in march 2012, AZN+BMS acquired it for 31$ in june 2012

    pasting some lines from a bloomberg article on 30th march 2012,

    [...“I don’t understand why you would turn down that bid,” from Bristol-Myers, Michael King, a New York-based analyst at Rodman & Renshaw LLC, said in a telephone interview.
    He said Amylin faces increased competition for insulin- related treatments and also has a debt burden that could deter other potential buyers.
    Amylin has $1.4 billion in net debt, more than 90 percent of biotechnology companies with at least $1 billion in market value, according to data compiled by Bloomberg.
    King recommends investors sell Amylin, which he estimates is worth less than $10 a share....]

    jfriedz87, hopes, speculations, thoughts can be seeded in minds of investors (reminds me of Brad Pitt starer Inception). The recent reuters leak suggested cubist offered 20$, and the analyst quoted in the same article said that 16$ is all OPTR would get, i highly suspect it to be a trick to make big holders sell their positions just a little above 16$, and the buyers take the rest when buyout happens at much higher pps.

    SortNewest  |  Oldest  |  Most Replied Expand all replies